Specific molecular differences found in the brains of individuals with post-traumatic stress disorder

A U.S.-based team analyzed 302 post mortem brains—including 101 from individuals who had experienced post-traumatic stress—and identified specific epigenetic molecular differences in those with this disorder. Furthermore, these changes can vary depending on sex or the age at which the trauma occurred. According to the authors, who published their findings in Cell Reports, this type of research could eventually contribute to the development of more individualized treatments.

Expert reactions

Juan Nácher - estrés postraumático EN

Juan Nácher

Professor of Cell Biology at the Neuroplasticity Unit of the Institute of Biotechnology and Biomedicine at the University of Valencia
Science Media Centre Spain

My impression is that, overall, this is a good article, with very interesting findings, particularly with regard to PTSD (post-traumatic stress disorder). It does, however, have some very significant limitations which call for caution when interpreting the results.

The study highlights differences in the epigenetics of various brain regions in PTSD. Although there was already evidence of these alterations in blood and saliva, this is the first time a comprehensive study has been carried out on post-mortem brains. Furthermore, the study reveals that epigenetic alterations do not occur uniformly across the brains of patients with PTSD; rather, there are substantial differences between different brain regions, which could indicate greater vulnerability in these regions or a greater impact of traumatic experiences on them. Of particular interest is the finding of a possible influence of traumatic experiences during adulthood on epigenomic modifications, as well as an apparent reduction in the number of oligodendrocytes—the myelin-producing cells—in the amygdala.

This is relevant because this region of the brain processes traumatic and fear-related memories, and many neuroimaging studies in humans with PTSD and in animal models of this condition have revealed structural and functional alterations. Alterations in the oligodendrocyte genome may influence the connectivity of amygdala neurons.

There are very significant limitations, which are inherent to working with post-mortem brains. The first is the absence of a conventional psychiatric assessment specifically for PTSD or MDD (major depressive disorder). Patients were selected primarily through retrospective telephone interviews with family members. This severely limits the observation of specific symptoms and the assessment of trauma (particularly if it occurred in childhood or adolescence). Nor is there any classification of patients according to the age of onset of the disorder or its duration. Although the number of cases is very large for a study using post-mortem material, the age range is enormous (18–85), and this may introduce significant bias. I do not have access to the detailed demographic table, but it does not appear that the variation in the time elapsed between death and the analysis or freezing of the samples has been taken into account. Nor does the influence of medication appear to have been considered, and this can have a very significant impact on epigenetics.

The author has declared they have no conflicts of interest
EN

Galí - Estrés

Raül Andero Galí

ICREA Research Professor, Director of Andero Lab and the Rodent Behavioral Core at the Autonomous University of Barcelona (UAB), and researcher in the Department of Psychobiology and Methodology of Health Sciences at the UAB and at the Carlos III Health Institute, CIBERSAM

Science Media Centre Spain

This study represents a significant advancement in our understanding of the molecular biology of individuals with post-traumatic stress disorder (PTSD) and depression. Obtaining such a large number of high-quality samples from different brain regions in patients with PTSD and depression is extraordinary, which is what makes this study so novel and exceptional.

To me, one of the most interesting findings is the reduction in the number of oligodendrocytes—cells that play a key role in communication between neurons—within the amygdala of patients with PTSD, but not in those with depression. A better understanding of the molecular biological differences between various mental health disorders will help us develop more personalized and effective treatments in the field of mental health.

The author has not responded to our request to declare conflicts of interest
EN

Alberto Ortiz - estrés postraumático EN

Alberto Ortiz Lobo

Doctor of Medicine and Psychiatrist at the Carlos III Day Hospital - La Paz University Hospital (Madrid)

Science Media Centre Spain

Neuroscientific studies relating to psychiatric diagnoses seek to bridge the gap between clinical mental phenomena and their brain-based explanation. There can be no doubt as to the inevitability—not only of the brain or the central nervous system, but of the entire body—in shaping what we understand as subjectivity; yet it is worth asking whether the complexity of the human condition can be reduced to a product of the brain.

This research is based on two misleading methodological constructs: the standardisation of such a diverse and context-dependent experience as the human response to an adverse event under the label of ‘post-traumatic stress disorder’, and its reduction to molecular phenomena within the brain.

Given the purely correlational nature of the data, it cannot explain the significance of the results obtained or the role of the structures involved in the phenomena under investigation. This is a recurring feature in neuroscientific studies of psychiatric diagnoses: the widespread search for causal explanations conflicts with the correlational nature of the findings and leads to interpretative leaps from correlations to causes.

Ultimately, what is presented as promising research that takes the brain-based explanation of post-traumatic stress disorder for granted is irrelevant to clinical practice; its approach may prove naïve in its disregard for human complexity and context, and runs the risk of being counterproductive, by focusing on brain tissue (dead, to add to the irony) and definitively dismissing people’s unique accounts of their life stories, individual experiences and the specific impacts of adverse events on each of them.

The author has not responded to our request to declare conflicts of interest
EN

Javier Costas - estrés postraumático EN

Javier Costas

Lead researcher of the Psychiatric Genetics group at the Health Research Institute of Santiago de Compostela (IDIS) and member of the Research Network on Addiction Primary Care (RIAPAd)

Science Media Centre Spain

This is an exploratory study with limited statistical power; consequently, many of the results may not be confirmed in subsequent analyses. The more conventional analysis, which seeks associations with methylation at the DNA position level, does not yield any notable results given the study’s limited statistical power.

The authors summarise the variability in methylation levels across the entire sample in the three brain regions, identifying latent factors (not measured directly) that encapsulate this variability. Several of these factors are associated with individual characteristics whose effect on methylation levels is well known, such as age, cell type composition or sex. Other individual characteristics with some evidence of affecting methylation levels were diagnosis and exposure to traumatic experiences. However, due to the small sample size, it was not possible to go beyond detecting the general effect, without identifying specific genes involved. Nevertheless, this is significant as it lays the groundwork for subsequent, more powerful studies that may identify genes and biological functions associated with differences in methylation levels resulting from traumatic experiences.

A clear limitation of the study is that it does not take into account many important individual characteristics, such as medication, alcohol use and other drugs. It should be borne in mind that a very significant proportion of patients with post-traumatic stress disorder (PTSD) have psychiatric (primarily depression) and substance-use comorbidities. Therefore, by failing to account for these variables, the results may identify mechanisms that are more closely related to these consequences of suffering from PTSD than to the pathophysiology of the disorder itself.

Finally, the findings regarding the different proportion of oligodendrocytes in patients with post-traumatic stress disorder are supported by genomic studies—which the authors have overlooked—indicating that genetic susceptibility to the disorder is concentrated not only in genes important for neuronal physiology, but also in those involved in oligodendrocyte physiology.

The author has not responded to our request to declare conflicts of interest
EN

Leza - Estrés

Juan Carlos Leza

Catedrático en la facultad de Medicina de la Universidad Complutense (Madrid) y miembro del CIBER de Salud Mental – ISCIII
Science Media Centre Spain

The work is published in a well-known journal within the field of cell biology—one that employs external peer review, is ranked in the top quartile (Q1) for its area, and so on. The presentation and justification of the topic, the description of the biological samples (brain tissue from 100 individuals who died with a diagnosis of major depressive disorder, PTSD, or as controls), and the application of the techniques are all well documented. The techniques themselves are established and appropriate for the study's objectives. The authors also clearly outline the study's limitations (such as issues related to sample enrichment) and disclose any potential conflicts of interest.

The authors—members of an international consortium that has been publishing research for over a decade—present a more sophisticated study than others previously released by the same group. They examine changes in specific brain nuclei that are crucial for regulating mood and stress—areas fundamental to understanding the pathophysiology (as well as the symptoms and treatment response) of major depressive disorder and PTSD.

This is not a pioneering study, in the sense that other research has already evaluated DNA methylation in the brain within the context of neuropsychiatric conditions. Changes in DNA methylation in the human brain indicate that the epigenome of those cells has been altered. While the genetic sequence itself remains unchanged, these modifications provide insight into the extent to which certain genes are activated or silenced.

Such changes can stem from a variety of factors—ranging from lifestyle and environmental influences to the natural passage of time and, of course, specific pathological processes. Determining their precise significance depends on where they occur, the cell type involved, and the direction of the change; however, further research beyond what is presented here is required to fully understand these implications.

The underlying principle has been understood for decades: neuropsychiatric disorders (among many others) result from an interplay between genes and the environment, which can lead a "vulnerable" individual to develop symptoms or manifest a clear clinical condition. In the case of depression... In the case of major depression or PTSD, the number of genes involved is much smaller than in other conditions, such as schizophrenia or autism spectrum disorders—yet, such genes do exist.

Through a process of interaction, certain vulnerable periods in life (childhood, adolescence, and even adulthood) can involve factors that modify—either by enhancing or silencing—the function of genes responsible for regulating synapses, neurotransmitters, the activity of specific neurons, and more. These processes lead to gene methylation. Such factors may include stress, abuse, exposure to toxins, persistently high levels of glucocorticoids, infections, or immunological challenges, among others.

Clearly, one of the primary strengths of this research is that it provides access to actual brain tissue—something impossible to achieve in a living patient (as brain biopsies cannot, obviously, be performed). The closest we can get is by analyzing, for example, cerebrospinal fluid—a procedure that carries risks and requires ethical justification—or by examining samples such as blood, urine, or saliva. Significant effort has been invested in identifying biomarkers within these peripheral samples that could serve for prognosis, predicting therapeutic response, or diagnosing brain disorders. While we will likely get closer to this goal in the future, we cannot currently guarantee that the mediators found in an individual’s plasma or blood are the same—or present at the same concentrations—as those found within the brain, or within a specific brain region or circuit.

It is true that neuroimaging techniques allow us to observe the quantity and location of markers of brain activity in living individuals; however, we are still far from being able to apply these biomarkers in a clinical setting.

In the meantime, studies using post-mortem tissue offer the advantage of examining the very tissue in which the disease resides—though many other variables must be taken into account, such as the time elapsed since death, the stability of the tissue prior to freezing or fixation, and various other factors. ...many factors, such as the ultimate cause of death, the presence of drugs or toxic substances at that time, etc.

In any case, the discovery—as reported by these authors—of changes in gene methylation in patients with depression and PTSD is definitely an important step toward personalized medicine. The study accounts for significant factors, such as age and sex. There is still a long way to go, but the goal is to be able to use these "markers" to clearly diagnose a condition or predict its response to a specific treatment—and, of course, to attempt to devise pharmacological (or non-pharmacological) strategies to "restore to normal" those processes that modulate gene activity.

[Regarding potential limitations] In general, I would like to emphasize that correlation does not equal causation: a change—in this case, in the methylation of a gene—does not necessarily explain the phenotype (as is the case with the polygenic conditions discussed in the article). Furthermore, one must also consider post-mortem effects; these studies utilize tissue from deceased donors, involving variables such as the post-mortem interval, cause of death, and medication use. And, of course, we are still waiting to see whether these findings—much like others already published along the same lines—can be translated into clinical practice and real-world application."

 

The author has declared they have no conflicts of interest
EN
Publications
Journal
Cell Reports
Publication date
Authors

Wylie et al.

Study types:
  • Research article
  • Peer reviewed
  • People
The 5Ws +1
Publish it
FAQ
Contact